Fineline Cube

Follow:
14409 Articles
Alteogen Secures Exclusive Licensing Deal with Daiichi Sankyo for Subcutaneous Enhertu
CompanyDeals

Alteogen Secures Exclusive Licensing Deal with Daiichi Sankyo for Subcutaneous Enhertu

Baheal Pharmaceutical Group Leads USD 78 Million Investment in ZAP Surgical Systems
CompanyDeals

Baheal Pharmaceutical Group Leads USD 78 Million Investment in ZAP Surgical Systems

Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China
CompanyDeals

Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China

AstraZeneca's Tezspire Meets Phase III Co-Primary Endpoints in CRSwNP Study
CompanyDrug

AstraZeneca’s Tezspire Meets Phase III Co-Primary Endpoints in CRSwNP Study

Sino Medical Sciences Technology Secures Marketing Approval in Peru for HT Supreme Stent System
CompanyMedical Device

Sino Medical Sciences Technology Secures Marketing Approval in Peru for HT Supreme Stent System

Jiangsu Kanion Pharmaceutical Gets FDA Approval to Test KYS202004A for Psoriasis
CompanyDrug

Jiangsu Kanion Pharmaceutical Gets FDA Approval to Test KYS202004A for Psoriasis

J&J Submits Regulatory Filings for Darzalex Faspro and Subcutaneous Daratumumab
CompanyDrug

J&J Submits Regulatory Filings for Darzalex Faspro and Subcutaneous Daratumumab

Jiangsu Hengrui Medicine Receives NMPA Clearance for Multiple Clinical Trials of Oncology Drugs
CompanyDrug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for Multiple Clinical Trials of Oncology Drugs

Alphamab Oncology Presents JSKN033 Phase I/II Study Results at SITC 2024
CompanyDrug

Alphamab Oncology Presents JSKN033 Phase I/II Study Results at SITC 2024

Sino Biopharmaceutical Ltd Receives NMPA Approval for KRAS G12C Inhibitor Garsorasib
CompanyDrug

Sino Biopharmaceutical Ltd Receives NMPA Approval for KRAS G12C Inhibitor Garsorasib

Daiichi Sankyo and Alteogen Sign $300 Million Deal to Develop Subcutaneous Enhertu
CompanyDeals

Daiichi Sankyo and Alteogen Sign $300 Million Deal to Develop Subcutaneous Enhertu

Dizal Pharmaceutical Submits NDA to FDA for Sunvozertinib as NSCLC Therapy
CompanyDrug

Dizal Pharmaceutical Submits NDA to FDA for Sunvozertinib as NSCLC Therapy